Immunotherapy for prostate cancer: what's the future?
Prostate cancer is the most common noncutaneous cancer and second leading cause of cancer death among US men. A greater understanding of basic immunologic principles has led to a variety of new techniques,which has led to advancements in prostate cancer vaccines. This article discusses the rationale for the development of antibody-based therapy and vaccines therapy, including whole tumor cells, dendritic cells, and pox viral vectors. A summary of selected clinical studies incorporating these strategies and new approaches incorporating a combination of immunotherapy with traditional treatments for prostate cancer is presented.
Arlen
Philip M
PM
Clinical Research Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, MSC 1750, Bethesda, MD 20892-1750, USA. pa52s@nih.gov
Dahut
William L
WL
Gulley
James L
JL
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019496:Cancer Vaccines; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive / Q000379:methods; D008297:Male; D017430:Prostate-Specific Antigen / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen